Medical discoveries, organised by the questions that matter.
The latest edition separates breakthroughs into six focused areas. Every story shows the evidence level, links to the original source and includes a Healthway explanation of what the result does — and does not — mean.
Cancer Treatment
New systemic therapies, immunotherapy and precision oncology — with approval pathway and trial phase clearly labelled.
New iberdomide combination receives accelerated approval for previously treated multiple myeloma
The FDA has added a new oral CELMoD-based combination after a large randomized trial showed substantially deeper MRD-negative responses.
Read Healthway summary →
Oncolytic viral therapy plus nivolumab approved for advanced melanoma after PD-1 treatment
A genetically modified virus is now part of an FDA-approved immunotherapy strategy for a defined group of advanced melanoma patients.
Read Healthway summary →
First-in-class FcRH5×CD3 bispecific antibody shows activity in heavily pretreated myeloma
A fixed-duration cevostamab programme produced responses in a difficult late-line multiple myeloma population.
Read Healthway summary →Autoimmune Diseases
High-quality trials in lupus, dermatomyositis and immune-resetting cell therapy.
Oral TYK2–JAK1 inhibition produces broad improvement in dermatomyositis
The phase 3 VALOR trial found that brepocitinib improved muscle, skin and functional outcomes and allowed greater steroid reduction.
Read Healthway summary →
Obinutuzumab improves disease control in active systemic lupus erythematosus
The ALLEGORY trial provides phase 3 evidence that deeper B-cell depletion can improve global lupus disease activity when added to standard therapy.
Read Healthway summary →
Temporary mRNA CAR-T therapy points toward an outpatient 'immune reset' for myasthenia gravis
A BCMA-directed RNA CAR-T approach produced durable clinical effects without lymphodepletion in a small randomized study.
Read Healthway summary →Genetic Diseases
Gene editing, gene replacement and treatments aimed at the molecular cause of rare inherited disease.
CRISPR-based Casgevy expands to children from age two with sickle cell disease or transfusion-dependent β-thalassaemia
The age expansion brings gene-edited autologous stem-cell therapy to much younger children with severe inherited blood disorders.
Read Healthway summary →
First gene therapy approved for OTOF-associated inherited hearing loss
Otarmeni uses a dual-AAV system to deliver functional OTOF genetic material directly to inner-ear hair cells.
Read Healthway summary →
First approved therapy aimed at neurological manifestations of Hunter syndrome
Avlayah is designed to address a major limitation of conventional enzyme therapy: reaching the central nervous system.
Read Healthway summary →Longevity
Aging biology without hype: human data, mechanisms and early therapeutic hypotheses are kept separate.
Aging stem cells may drive chronic inflammation through maladaptive 'trained immunity'
New work identifies loss of the mitochondrial regulator SIRT3 in hematopoietic stem cells as a potential upstream driver of inflammaging.
Read Healthway summary →
Network map of 2,358 longevity-linked genes identifies drug-repurposing candidates for aging biology
Researchers mapped the molecular hallmarks of aging onto the human protein interactome and screened thousands of compounds computationally.
Read Healthway summary →
Human calorie-restriction study identifies a possible molecular link to lower 'inflammaging'
Proteomic analysis of CALERIE participants suggests that modest long-term calorie restriction may dampen complement-related inflammatory signalling.
Read Healthway summary →Diabetes
Disease-modifying type 1 diabetes therapy, once-weekly insulin and new long-term outcome evidence.
Tzield becomes the first FDA-approved treatment aimed at preserving insulin production after recent stage 3 type 1 diabetes diagnosis in children
The anti-CD3 therapy now has a new indication intended to slow loss of endogenous insulin production in recently diagnosed pediatric type 1 diabetes.
Read Healthway summary →
Once-weekly basal insulin Awiqli approved for adults with type 2 diabetes
Insulin icodec compresses basal insulin dosing from seven injections per week to one for eligible adults with type 2 diabetes.
Read Healthway summary →
Large real-world study links GLP-1 use in type 1 diabetes with lower cardiovascular and kidney risk
A national electronic-health-record analysis found lower rates of major cardiovascular events and end-stage kidney disease among GLP-1RA initiators.
Read Healthway summary →Weight Loss & Obesity
The rapidly changing obesity-treatment field, including oral GLP-1 agents and preservation of lean mass.
New oral nonpeptide GLP-1 VCT220 produces up to 9.7% mean weight loss at 16 weeks
One of the newest oral small-molecule GLP-1 candidates reported rapid weight loss and metabolic improvement in a 250-participant phase II trial.
Read Healthway summary →
Oral aleniglipron reaches double-digit weight loss in phase 2b study
The small-molecule GLP-1 receptor agonist produced placebo-adjusted mean weight reductions up to 11.3% over 36 weeks.
Read Healthway summary →
Can weight-loss treatment preserve more muscle? Apitegromab study targets lean-mass loss during tirzepatide therapy
A myostatin-targeting antibody preserved more lean mass when combined with tirzepatide in a proof-of-concept obesity trial.
Read Healthway summary →Interesting research is not automatically personal medical advice.
If a new treatment may be relevant to your condition, discuss the evidence in the context of your diagnosis, medicines and risk profile.